Lung Cancer News and Research

Latest Lung Cancer News and Research

IASLC to host 5th Latin American Conference on Lung Cancer in Brazil

The International Association for the Study of Lung Cancer (IASLC) is hosting the 5th Latin American Conference on Lung Cancer July 25 to 27 in Rio de Janeiro, Brazil. Nearly 1,000 medical professionals will gather to discuss the latest lung cancer research and treatment.

23 Jun 2012

ATS task force recommends annual lung cancer screening using LDCT

A lung screening and surveillance task force, established by the American Association for Thoracic Surgery (AATS) and led by medical professionals from Brigham and Women's Hospital (BWH), is strongly recommending new guidelines for lung cancer screening. The guidelines were published this week in the online edition of the Journal of Thoracic and Cardiovascular Surgery (JTCVS).

22 Jun 2012

Viewpoints: For Fla. small business owner, loss of health law would be 'real blow;' Effort to silence Mich. legislators backfires

Running a small business with four employees, I've got a lot hanging in the balance as the Supreme Court deliberates on the healthcare law. The legal challenge to the law was launched here in Florida with a small business lobby group as a plaintiff in the case. But if you're thinking that means small business people like me want to see the law rolled back, think again. The simple fact is, the healthcare law is saving our business serious money and saving our healthcare benefits.

20 Jun 2012

Multi-institutional research uncovers new mechanism for treatment of lung cancer

A multi-institutional research study has uncovered a new mechanism that may lead to unique treatments for lung cancer, one of the leading causes of death worldwide.

18 Jun 2012

Infinity voluntarily stops saridegib Phase 2 trial for chondrosarcoma

Infinity Pharmaceuticals, Inc. today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival.

18 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

Stereotactic ablative radiotherapy benefits stage I non-small cell lung cancer patients

Until recently, many elderly patients with stage I non-small cell lung cancer were left untreated because treatment may not improve their quality of life. However, stereotactic ablative radiotherapy (SABR) has become one of the standards of treatment for these patients. The outpatient treatment given over a two-week period allows frail patients to undergo the treatment.

16 Jun 2012

Surgeon specialty, hospital volume important factors in patient outcomes

In other studies, outcomes of specific surgeries has been shown to improve when performed at high-volume centralized centers. Researchers from the Netherlands Cancer Institute wanted to understand if patients undergoing lung cancer resections would benefit from having their procedures performed in a high-volume specialized center.

16 Jun 2012

Chemotherapy improves survival for patients with SCLC and LCNEC

Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that patients with limited large cell neuroendocrine tumors or with limited stage small-cell lung cancer who were treated with perioperative chemotherapy and surgery had better overall survival outcomes than patients treated with surgery alone.

16 Jun 2012

Roundup: Iowa redesign of mental health services raises concerns; Mich. lawmakers opposed to abortion restrictions are 'silenced'

State leaders hope their mental health redesign will bring better services to (rural areas of Iowa), but many front-line administrators doubt they'll see significant improvements soon. In fact, some worry that services could erode over the next year as money and some financial responsibilities are shifted from the counties to the state. Some long-term improvements are possible, they say, but cash likely will run short in the next few months.

15 Jun 2012

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) that treats cancer patients with promising new drugs.

15 Jun 2012

Sanovas receives U.S. patent allowance for microsurgical lung cancer technology

Sanovas, Inc., a medical technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its first patent relating to systems and methods for the removal of unwanted biological material, such as tissue growths and tumors, in hard-to-reach bodily cavities.

15 Jun 2012

Antibody that blocks programmed cell death benefits cancer patients

A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).

14 Jun 2012

Cancer experts call for global action on diesel fumes

Diesel exhaust fumes have been classified as carcinogenic to humans by the International Agency for Research on Cancer, following a week-long meeting of international experts.

14 Jun 2012

Scientists discover one of the most important cellular mechanisms behind meningioma

Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor. A report on the discovery, published in the journal Molecular Cancer Research, could lead the way to the discovery of better drugs to attack these crippling tumors, the scientists say.

14 Jun 2012

WHO agency classifies diesel exhaust as 'carcinogenic'

The International Agency for Research on Cancer (IARC), the WHO's cancer arm, on Tuesday announced it has reclassified diesel engine exhaust from "probably carcinogenic" to "carcinogenic," the U.N. News Centre reports, noting the decision came "after a week-long meeting of international experts, and the agency based its decision on sufficient evidence that exposure is associated with an increased risk for lung cancer."

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Significant increase in use of CT, MRI and PET imaging over the last two decades

Among six large integrated health care systems between 1996 and 2010 there was a substantial increase in the use of advanced diagnostic imaging, including approximately a tripling of the use of computed tomography and nearly a quadrupling of the use of magnetic resonance imaging, as well as a substantial increase in estimated radiation exposure, according to a study in the June 13 issue of JAMA.

13 Jun 2012

Researchers find pathway for origin and growth of the most common form of brain and spinal cord tumor – meningioma

Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor.

12 Jun 2012